1. A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose Chemotherapy
by Elizabeth J. Shpall, C. Fred LeMaistre, Kent Holland, Edward Ball, Roy B. Jones, Rein Saral, Cindy Jacobs, Shelly Heimfeld, Ronald Berenson, and Richard Champlin
Blood
Volume 90(11):
December 1, 1997
©1997 by American Society of Hematology

2. Flow diagram of autologous marrow processing procedure.
Flow diagram of autologous marrow processing procedure. To remain on the study, at each step outlined, patients were required to have a minimum (min) of 3.0 × 108 total nucleated cells per kilogram patients' weight (TNC/kg) at marrow harvest, and 2.0 × 108 TNC/kg in the buffy coat fraction with 0.5 × 108 TNC/kg as a backup fraction.
Elizabeth J. Shpall et al. Blood 1997;90:
©1997 by American Society of Hematology

3. The progression-free survival for patients on both arms of the study was 31% (P = .492).
Elizabeth J. Shpall et al. Blood 1997;90:
©1997 by American Society of Hematology